Non-Hodgkin lymphoma cells have higher expression of CB1 and CB2 cannabinoid receptors in the mRNA of the cell compared to regular cells, ready to be stimulated by cannabinoids to self-destruct. A recent study shows that certain cannabinoid combinations effectively treat My-La and HuT-78 cell lines of lymphoma, resulting in up to 50% 86% cell death respectively.
S4: a compound consisting of CBD (98.3%), THC (0.3%), cannabigerol (CBG 0.2%), a-bisabolol (0.9%) and cannabidivarin (CBDV 0.09%).
S5: a compound consisting of CBG (58.8%) and CBD (38.2%), THC (0.7%) and cannabichromene (CBC 0.4%).
DOXO: doxorubicin aka Adriamycin ® or Rubex®
The following cannabinoid compounds were found to have anti-lymphoma properties at varying concentrations:
- CBD+CBG
- CBD+CBG+CBC
- CBD+CBG+THC
- CBD+CBG+THC+CBC
Pure CBD in some concentrations causes My-La cell proliferation rather than apoptosis (death); however, when added to other cannabinoids, like CBG, THC, or CBC it has anti-cancer properties.
Source:
Mazuz, M., Tiroler, A., Moyal, L., Hodak, E., Nadarajan, S., Vinayaka, A. C., Gorovitz-Haris, B., Lubin, I., Drori, A., Drori, G., Cauwenberghe, O. V., Faigenboim, A., Namdar, D., Amitay-Laish, I., & Koltai, H. (2020). Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo. Oncotarget, Vol. 11(issue 13), Pp. 1141–1156.